Assays of amyloid beta, phosphorylated tau, and total tau protein concentrations in cerebrospinal fluid (CSF) support AD diagnosis, predict AD neuropathology, and are valuable biomarkers in AD research (1). Here, MAPT is linked to Alzheimer disease.